|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: INTS3 |
Gene summary for INTS3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | INTS3 | Gene ID | 65123 |
| Gene name | integrator complex subunit 3 | |
| Gene Alias | C1orf193 | |
| Cytomap | 1q21.3 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | Q68E01 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 65123 | INTS3 | LZE4T | Human | Esophagus | ESCC | 1.37e-04 | 1.24e-01 | 0.0811 |
| 65123 | INTS3 | LZE7T | Human | Esophagus | ESCC | 5.57e-03 | 3.12e-01 | 0.0667 |
| 65123 | INTS3 | LZE8T | Human | Esophagus | ESCC | 2.72e-02 | 1.29e-01 | 0.067 |
| 65123 | INTS3 | LZE24T | Human | Esophagus | ESCC | 2.50e-11 | 2.47e-01 | 0.0596 |
| 65123 | INTS3 | P1T-E | Human | Esophagus | ESCC | 1.55e-06 | 4.41e-01 | 0.0875 |
| 65123 | INTS3 | P2T-E | Human | Esophagus | ESCC | 5.57e-16 | 2.44e-01 | 0.1177 |
| 65123 | INTS3 | P4T-E | Human | Esophagus | ESCC | 7.26e-11 | 1.38e-01 | 0.1323 |
| 65123 | INTS3 | P5T-E | Human | Esophagus | ESCC | 3.42e-15 | 3.32e-01 | 0.1327 |
| 65123 | INTS3 | P8T-E | Human | Esophagus | ESCC | 1.56e-10 | 2.33e-01 | 0.0889 |
| 65123 | INTS3 | P9T-E | Human | Esophagus | ESCC | 1.06e-11 | 2.58e-01 | 0.1131 |
| 65123 | INTS3 | P10T-E | Human | Esophagus | ESCC | 3.71e-15 | 3.20e-01 | 0.116 |
| 65123 | INTS3 | P11T-E | Human | Esophagus | ESCC | 2.47e-02 | 1.84e-01 | 0.1426 |
| 65123 | INTS3 | P12T-E | Human | Esophagus | ESCC | 2.89e-07 | 1.33e-01 | 0.1122 |
| 65123 | INTS3 | P15T-E | Human | Esophagus | ESCC | 2.98e-14 | 3.23e-01 | 0.1149 |
| 65123 | INTS3 | P16T-E | Human | Esophagus | ESCC | 3.43e-11 | 2.22e-01 | 0.1153 |
| 65123 | INTS3 | P17T-E | Human | Esophagus | ESCC | 1.82e-02 | 1.68e-01 | 0.1278 |
| 65123 | INTS3 | P20T-E | Human | Esophagus | ESCC | 4.31e-10 | 2.00e-01 | 0.1124 |
| 65123 | INTS3 | P21T-E | Human | Esophagus | ESCC | 2.94e-13 | 2.92e-01 | 0.1617 |
| 65123 | INTS3 | P22T-E | Human | Esophagus | ESCC | 1.14e-10 | 2.26e-01 | 0.1236 |
| 65123 | INTS3 | P23T-E | Human | Esophagus | ESCC | 3.04e-11 | 3.11e-01 | 0.108 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003447015 | Esophagus | ESCC | ncRNA processing | 300/8552 | 395/18723 | 3.09e-35 | 3.26e-32 | 300 |
| GO:003466012 | Esophagus | ESCC | ncRNA metabolic process | 346/8552 | 485/18723 | 4.35e-31 | 2.51e-28 | 346 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:001021217 | Esophagus | ESCC | response to ionizing radiation | 110/8552 | 148/18723 | 1.11e-12 | 4.78e-11 | 110 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
| GO:00448394 | Esophagus | ESCC | cell cycle G2/M phase transition | 103/8552 | 148/18723 | 3.09e-09 | 6.67e-08 | 103 |
| GO:00000864 | Esophagus | ESCC | G2/M transition of mitotic cell cycle | 96/8552 | 137/18723 | 6.00e-09 | 1.23e-07 | 96 |
| GO:00070934 | Esophagus | ESCC | mitotic cell cycle checkpoint | 90/8552 | 129/18723 | 2.49e-08 | 4.69e-07 | 90 |
| GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
| GO:19019883 | Esophagus | ESCC | negative regulation of cell cycle phase transition | 151/8552 | 249/18723 | 1.28e-06 | 1.57e-05 | 151 |
| GO:004593013 | Esophagus | ESCC | negative regulation of mitotic cell cycle | 143/8552 | 235/18723 | 1.84e-06 | 2.15e-05 | 143 |
| GO:190199113 | Esophagus | ESCC | negative regulation of mitotic cell cycle phase transition | 112/8552 | 179/18723 | 3.69e-06 | 4.03e-05 | 112 |
| GO:00103891 | Esophagus | ESCC | regulation of G2/M transition of mitotic cell cycle | 64/8552 | 94/18723 | 9.21e-06 | 8.82e-05 | 64 |
| GO:19027491 | Esophagus | ESCC | regulation of cell cycle G2/M phase transition | 68/8552 | 102/18723 | 1.48e-05 | 1.33e-04 | 68 |
| GO:00109721 | Esophagus | ESCC | negative regulation of G2/M transition of mitotic cell cycle | 41/8552 | 60/18723 | 3.25e-04 | 1.91e-03 | 41 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| INTS3 | SNV | Missense_Mutation | c.1439N>T | p.Lys480Met | p.K480M | Q68E01 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AO-A0J6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| INTS3 | SNV | Missense_Mutation | c.2131N>C | p.Ala711Pro | p.A711P | Q68E01 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| INTS3 | SNV | Missense_Mutation | novel | c.2857N>T | p.His953Tyr | p.H953Y | Q68E01 | protein_coding | tolerated(0.93) | possibly_damaging(0.888) | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |
| INTS3 | SNV | Missense_Mutation | novel | c.1044C>G | p.Asp348Glu | p.D348E | Q68E01 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-BH-A8FZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| INTS3 | SNV | Missense_Mutation | c.1870N>A | p.Glu624Lys | p.E624K | Q68E01 | protein_coding | tolerated(0.37) | probably_damaging(0.953) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| INTS3 | SNV | Missense_Mutation | c.2011N>G | p.Leu671Val | p.L671V | Q68E01 | protein_coding | tolerated(0.96) | benign(0) | TCGA-D8-A147-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine | SD | |
| INTS3 | SNV | Missense_Mutation | novel | c.928G>C | p.Glu310Gln | p.E310Q | Q68E01 | protein_coding | deleterious(0.02) | probably_damaging(0.986) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
| INTS3 | insertion | In_Frame_Ins | novel | c.1516_1516+1insATT | p.Val506delinsAspPhe | p.V506delinsDF | Q68E01 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| INTS3 | insertion | Frame_Shift_Ins | novel | c.1359_1360insTCCTTGGAATGTGCTGATTCAGATATGACAA | p.Gln454SerfsTer34 | p.Q454Sfs*34 | Q68E01 | protein_coding | TCGA-BH-A0DP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD | ||
| INTS3 | insertion | Nonsense_Mutation | novel | c.311_312insTTAAAGAAATCAGGTCACCTGTTTATGGTTTCCACATTTTAGATTTTG | p.Ala104_Gln105insTer | p.A104_Q105ins* | Q68E01 | protein_coding | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |